Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review.
Hypereosinophilic syndrome (HES) is a multisystem disease with a significant mortality rate. It is characterized by peripheral blood eosinophilia and infiltration of eosinophils into many organs including skin. We describe a patient with cutaneous, pulmonary, and gastric symptoms of HES. He was first treated with systemic and topical corticosteroids, antihistamines, and photochemotherapy. Therapy was switched to interferon-alpha, because we had to consider side effects of corticosteroids and no significant improvement had been achieved. During the period of usage of interferon-alpha for 50 weeks, his symptoms of HES nearly cleared. There has been no recurrence in the eight months since the discontinuation of interferon-alpha therapy.
Yoon
T Y
TY
Department of Dermatology, College of Medicine, Chungbuk National University, Republic of Korea.
Ahn
G B
GB
Chang
S H
SH
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy*; D007155:Immunologic Factors / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D008168:Lung / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction; D012867:Skin / Q000473:pathology; D013270:Stomach / Q000473:pathology
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D006634:Histamine H1 Antagonists; D007155:Immunologic Factors; D016898:Interferon-alpha; D011239:Prednisolone